Abstract
Despite the advances in the management of ovarian cancer, the disease remains the leading cause of death from gynecological malignancies. As it generally remains confined to the peritoneal cavity, ovarian cancer is an attractive target for radioimmunotherapy via the intraperitoneal route of administration. Several clinical trials have been carried out investigating radiolabeled monoclonal antibodies and the results seem promising, especially in patients with small-volume residual disease after conventional therapy. Intraperitoneal radioimmunotherapy has yet to prove itself as an important part of the treatment of ovarian cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
